Analysis Of Cytokine Messenger Rna Profile In Patients With Inflammatory Bowel Disease.

Background: Infliximab, a chimeric monoclonal antibody to TNFa. is approved for short-term treatment of active Crohu's disease (CD) and fistulizing CD.Long-term safety and efficacy in CD is currently under investigation.lnfliximab is also approved for long-term treatment of patients with rheumatoid arthritis (RA).Aim: To evaluate the safety and efficacy of 54 wks of regular therapy with infliximab in an RCT in pts with active RA not adequately responding to methotrexate (MTX).Methods: PIs continued MTX therapy and were assigned to I of 5 dosing groups; receiving either placebo (pbo) or infliximab (3 or 10 mg/kg) every 4 or 8 weeks following an induction regimen of infusions at wks 0, 2 and 6. 428 pts were studied.Results: Infliximab was generally well-tolerated.Through 6224